MDPI and ACS Style
Masuda, N.; Yoshinami, T.; Ikeda, M.; Mizutani, M.; Yamaguchi, M.; Komoike, Y.; Takashima, T.; Yoshidome, K.; Tsurutani, J.; Iwamoto, M.;
et al. Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers 2021, 13, 4399.
https://doi.org/10.3390/cancers13174399
AMA Style
Masuda N, Yoshinami T, Ikeda M, Mizutani M, Yamaguchi M, Komoike Y, Takashima T, Yoshidome K, Tsurutani J, Iwamoto M,
et al. Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers. 2021; 13(17):4399.
https://doi.org/10.3390/cancers13174399
Chicago/Turabian Style
Masuda, Norikazu, Tetsuhiro Yoshinami, Masahiko Ikeda, Makiko Mizutani, Miki Yamaguchi, Yoshifumi Komoike, Tsutomu Takashima, Katsuhide Yoshidome, Junji Tsurutani, Mitsuhiko Iwamoto,
and et al. 2021. "Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214" Cancers 13, no. 17: 4399.
https://doi.org/10.3390/cancers13174399